Pay­back? An­a­lysts say Sarep­ta was blind­sided by an FDA re­jec­tion dri­ven by reg­u­la­to­ry re­venge

In one of the least an­tic­i­pat­ed moves of the year, the FDA has re­ject­ed Sarep­ta’s ap­pli­ca­tion for an ac­cel­er­at­ed ap­proval of its Duchenne MD drug golodirsen af­ter fret­ting over safe­ty is­sues.

In a state­ment that ar­rived af­ter the bell on Mon­day, Sarep­ta ex­plained the CRL, say­ing:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER